S&P 500

5.996,66

1,00%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NYSE
ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (ADCT) Notícias

ADCT

ADC Therapeutics (ADCT)

ADC Therapeutics SA

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NYSE:ADCT

1 2 3 4 5 6 7 8 9 10 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
13/01/2025	14:20	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ADCT	ADC Therapeutics SA
02/01/2025	18:05	PR Newswire (US)	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan	NYSE:ADCT	ADC Therapeutics SA
30/12/2024	18:30	PR Newswire (US)	ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma	NYSE:ADCT	ADC Therapeutics SA
11/12/2024	09:30	PR Newswire (US)	ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	NYSE:ADCT	ADC Therapeutics SA
09/12/2024	22:42	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ADCT	ADC Therapeutics SA
09/12/2024	09:30	PR Newswire (US)	ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma	NYSE:ADCT	ADC Therapeutics SA
06/12/2024	09:30	PR Newswire (US)	ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial	NYSE:ADCT	ADC Therapeutics SA
07/11/2024	12:44	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:ADCT	ADC Therapeutics SA
07/11/2024	09:30	PR Newswire (US)	ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update	NYSE:ADCT	ADC Therapeutics SA
05/11/2024	11:47	PR Newswire (US)	ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting	NYSE:ADCT	ADC Therapeutics SA
04/11/2024	09:15	PR Newswire (US)	ADC Therapeutics to Present at November Investor Conferences	NYSE:ADCT	ADC Therapeutics SA
31/10/2024	08:15	PR Newswire (US)	ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024	NYSE:ADCT	ADC Therapeutics SA
23/09/2024	17:39	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NYSE:ADCT	ADC Therapeutics SA
23/09/2024	17:35	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NYSE:ADCT	ADC Therapeutics SA
13/09/2024	17:16	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NYSE:ADCT	ADC Therapeutics SA
03/09/2024	08:15	GlobeNewswire Inc.	ADC Therapeutics to Present at Upcoming Investor Conferences	NYSE:ADCT	ADC Therapeutics SA
14/08/2024	01:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NYSE:ADCT	ADC Therapeutics SA
06/08/2024	17:26	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NYSE:ADCT	ADC Therapeutics SA
06/08/2024	08:30	GlobeNewswire Inc.	ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update	NYSE:ADCT	ADC Therapeutics SA
30/07/2024	08:15	GlobeNewswire Inc.	ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024	NYSE:ADCT	ADC Therapeutics SA
08/07/2024	03:00	GlobeNewswire Inc.	Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development	NYSE:ADCT	ADC Therapeutics SA
27/06/2024	08:15	GlobeNewswire Inc.	ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes	NYSE:ADCT	ADC Therapeutics SA
06/06/2024	16:33	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NYSE:ADCT	ADC Therapeutics SA
30/05/2024	08:15	GlobeNewswire Inc.	ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference	NYSE:ADCT	ADC Therapeutics SA
15/05/2024	08:15	GlobeNewswire Inc.	ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	NYSE:ADCT	ADC Therapeutics SA
09/05/2024	08:15	GlobeNewswire Inc.	ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference	NYSE:ADCT	ADC Therapeutics SA
07/05/2024	17:06	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:ADCT	ADC Therapeutics SA
07/05/2024	17:02	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:ADCT	ADC Therapeutics SA
06/05/2024	08:30	GlobeNewswire Inc.	ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants	NYSE:ADCT	ADC Therapeutics SA
06/05/2024	07:10	GlobeNewswire Inc.	ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	NYSE:ADCT	ADC Therapeutics SA